Immix Biopharma (IMMX) Times Interest Earned (2021 - 2022)

Immix Biopharma has reported Times Interest Earned for 6 years, with the latest figure at -$30.29 in Q1 2026.

• Quarterly Times Interest Earned fell 182.38% year-over-year to -$30.29 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$101.15 (down 102.86% YoY) and the FY2025 annual result came in at -$1.18, up 17.65% from the prior year.
• Times Interest Earned retreated to -$30.29 in Q1 2026 per IMMX's latest filing, from -$28.84 in the prior quarter.
• Over five years, Times Interest Earned peaked at $417.03 in Q4 2022 and troughed at -$8259.0 in Q2 2022.
• A 5-year average of -$875.41 and a median of -$10.7 in 2024 frame the typical range for Times Interest Earned.
• The widest YoY moves for Times Interest Earned: up 161.68% in 2022, down 182850.63% in 2022.
• Over 5 years, Times Interest Earned stood at $417.03 in 2022, then tumbled by 100.17% to -$0.7 in 2023, then soared by 55.09% to -$0.32 in 2024, then tumbled by 9017.25% to -$28.84 in 2025, then decreased by 5.02% to -$30.29 in 2026.
• According to Business Quant data, Times Interest Earned over the past three periods registered -$30.29, -$28.84, and -$5.09 for Q1 2026, Q4 2025, and Q3 2025 respectively.